Search

Displaying results 1181 - 1190 of 7674 in total
  1. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.

  2. Drug

    Ferrous bisglycinate

    go.drugbank.com/drugs/DB11210
    Approved

    Ferrous bisglycinate is a chelate that is used as a source of dietary iron. Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and a nutritionally functional . It is found in foods for food e...

    Mixtures: FeRiva FA, Triveen-Duo DHA
  3. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    [A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. … [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents.

    Mixtures: XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA, XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADAProducts: Nra-dapagliflozin
  4. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. … [A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070]

    Synonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one
  5. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026. … [L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist.

  6. Drug

    Polidocanol

    go.drugbank.com/drugs/DB06811
    ApprovedInvestigational

    It is marketed under the brand names Asclera and Varithena.

  7. Drug

    Moxidectin

    go.drugbank.com/drugs/DB11431
    ApprovedInvestigationalVet approved

    Due to these modifications, moxidectin is classified as a second generation macrocyclic lactone. … [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970]

  8. Drug

    Inclisiran

    go.drugbank.com/drugs/DB14901
    ApprovedInvestigational

    [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults … [A225953,A225958] Lowering circulating plasma LDL-C levels offers an additional benefit of reducing the risk of cardiovascular disease (CVD) and improving cardiovascular outcomes, as hypercholesterolemia

  9. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    Epoetin alfa formulations can be administered intravenously or subcutaneously. … It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label].

    Products: EPO STADA 3333 IU/ML, EPO STADA 10000 IU/ML
  10. Drug

    Ergoloid mesylate

    go.drugbank.com/drugs/DB01049
    Approved

    [L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. … Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.